Background {#Sec1}
==========

Recent studies indicate a reduction of life expectancy by over a decade, in people diagnosed with type 1 diabetes (T1D) \[[@CR1]--[@CR3]\]. Given the duration of glycaemic exposure, the risk for diabetes-related vascular diseases is likely to be greater in childhood-onset compared to adult-onset T1D \[[@CR3]--[@CR6]\]. The burden of T1D greatly impacts upon the quality of life of children and their families \[[@CR7], [@CR8]\]. These poor outcomes have been highlighted by health policy advisers \[[@CR9]\] and are of relevance given the increasing worldwide incidence of childhood T1D \[[@CR10]--[@CR14]\], and in those aged under 5 years, in whom both prognosis and burden of disease are likely to be even worse \[[@CR15]--[@CR18]\]. The strongest modifiable predictor of complications in T1D patients is glycaemic control, which is measured as haemoglobin A1~c~ levels (HbA1~c~) \[[@CR19]--[@CR22]\]. Use of intensive insulin therapy in young children is associated with better glycaemic control (i.e. lower HbA1~c~ levels) \[[@CR23]\].

Results from a recent systematic review of 18 clinical trials (with a total of 2254 T1D participants and a mean follow-up duration across studies varying between 1 and 25 years) showed that targeting intensive glycaemic control (four or more insulin injections per day or insulin pump therapy) did not improve all-cause mortality, but it reduced the relative risk of the composite macrovascular outcomes (0.63; confidence interval (CI) 0.41 to 0.96; *P* = 0.03) and diabetic nephropathy (0.37; CI 0.27 to 0.50; *P* \< 0.00001), when compared to management with conventional insulin regimens (i.e. three or less insulin injections per day) \[[@CR24]\]. However, the review could not assess the effect of targeting intensive glycaemic control on patients younger than 18 years and no macrovascular or microvascular outcomes were reported in the four small trials (sample sizes between 14 and 34), three of which included newly diagnosed T1D patients under 18 years, probably due to the short follow-up period of up to 1.5 years \[[@CR25]--[@CR28]\].

An updated Cochrane review with 12 trials (with a mean follow-up duration across studies varying between 1 and 6.5 years) concluded that tight glycaemic control (compared to less intense treatment targets) was beneficial in younger patients (age not specified), at early stages of disease (retinopathy: RR 0.27 (95 % CI 0.18 to 0.42); *P* \< 0.00001; nephropathy: RR 0.56 (95 % CI 0.46 to 0.68); *P* \< 0.00001; neuropathy: RR 0.35 (95 % CI 0.23 to 0.53); *P* \< 0.00001) \[[@CR29]\]. However, this review contained just one trial in young children aged 6--15 years with diabetes duration of 1--2 years \[[@CR30]\], and most of the other included trials were conducted in the 1980s, when use of insulin pump therapy was less widespread.

Also, evidence from landmark studies indicates that improved glycaemic control in T1D through use of intensive insulin therapy is strongly associated with reduced complications risk and mortality \[[@CR19], [@CR31], [@CR32]\]. Results from the Diabetes Control and Complications Trial (DCCT), a multicenter, randomised controlled clinical trial of 1441 people (including 195 adolescents) with T1D (1983--1993), provided evidence that early intensive glycaemic control conferred a significant reduction in risk of microvascular and macrovascular complications compared to conventional treatment, an effect which continued in subsequent years even after equalisation of metabolic control \[[@CR21], [@CR31], [@CR33], [@CR34]\]. Importantly, reduced mortality was also observed with the use of early intensive versus conventional insulin therapy use (43 deaths versus 64 deaths respectively among 1429 participants; hazard ratio 0.67 (95 % CI 0.46--0.99)) after 27 years from entry into the trial \[[@CR31]\]. All-cause mortality was significantly higher among those with higher mean HbA1~c~ levels (hazard ratio (HR) = 1.56 (95 % CI 1.35--1.81 per 10 % relative increase in HbA1~c~); *P* \< 0.001) and with renal disease (HR = 8.51(95 % CI 4.45--16.27); *P* \< 0.001) during the 27-years of follow-up \[[@CR33], [@CR35]\].

Other studies have also suggested the beneficial effects of early glycaemic control in preventing future complications \[[@CR36], [@CR37]\]. Therefore, it appears that maintaining lower HbA1~c~ levels in the early years after diagnosis may be beneficial in adults for reducing future risk of complications, regardless of subsequent glycaemic control over the course of diabetes duration. Diabetologists use the term "metabolic memory" for these observations. However, the DCCT contained only 195 adolescents (13 to 17 years of age at entry), with T1D duration of 38 ± 20 months at the start of the trial \[[@CR38]\]. Hence, the effect of insulin intensification from or near to diagnosis has not been robustly assessed in childhood-onset T1D. It would be important to note that adult outcomes cannot be extrapolated to childhood due to important biological and psychosocial determinants such as puberty, insulin resistance and adolescent risk-taking behaviours that are less relevant in adults \[[@CR39]\].

Furthermore, some reports indicate that very early HbA1~c~ level track with future glycemic control, i.e. low or high HbA1~c~ levels within the first few months of diagnosis associate with low or high HbA1~c~ levels in later years, an effect which can persist for almost a decade \[[@CR31], [@CR40]--[@CR43]\]. These studies were from USA and Europe, but the age range, duration of T1D, treatment and follow-up varied across studies. Additionally, the use of intensive insulin therapy in early childhood T1D is increasing but is not universal \[[@CR44]\]. Also, many well-documented population-based registries lack robust and comparable data on glycemic control \[[@CR45]\].

Our review will investigate whether HbA1~c~ levels in the first 2 years following diagnosis of T1D in children predicts future risk of complications and will quantify the extent to which the level of glycaemia in the first 2 years of diabetes tracks in adulthood/with increasing diabetes duration. We will also investigate the predictors of early glycaemic control and how these may influence the paediatric TID management plan. Our analyses may highlight a need for a change in early care processes in children with T1D, by providing an argument for more intensive diabetes treatments than are currently undertaken.

Methods/study design {#Sec2}
====================

We will undertake two linked systematic reviews answering two main research questions, namely:Is higher early HbA1~c~ (within 2 years of T1D diagnosis) associated with later complications in child-onset T1D patients (childhood-onset T1D defined as onset ≤18 years)?What factors at diagnosis or soon after are associated with higher early HbA1~c~?

We will follow the methods for conducting systematic reviews, as described by the Evidence for Policy and Practice Information (EPPI) and Co-ordinating Centre \[[@CR46]\]. The review process will be in four phases. Phase 1 (completed): iterative scoping stage to define the research question, refine the search strategy and outline the inclusion/exclusion and quality assessment criteria. This was followed by identification of literature by searching of electronic databases. Phase 2: descriptive mapping and synthesis of existing evidence by number, types and quality attributes of research studies on the topic. Phase 3: detailed data extraction and in-depth synthesis of quantitative studies \[[@CR47]\]. Phase 4: thematic analysis of qualitative literature \[[@CR48]\], followed by integration of these findings with the quantitative evidence by using parallel synthesis or mixed method approach \[[@CR49]\]. This methodology of using qualitative research to explain quantitative evidence will provide a deeper understanding of the predictors influencing early glycaemic control in children and young people.

Search strategy {#Sec3}
---------------

After a number of initial iterative scoping searches, with input from experts in the field, the search strategy was refined to maximise sensitivity and specificity in capturing key publications. Three sets of search terms were used (see search strategy in Table [1](#Tab1){ref-type="table"}) relating to population (children and young people diagnosed with TID), exposure (terms to capture observational, intervention, qualitative studies and review articles relating to early diabetes control) and outcome (complications, mortality or metabolic memory).Table 1Search strategy for research questions: Does early glycaemic control (intervention within two years post diagnosis) in childhood-onset T1D have an impact on subsequent risk of complications in childhood and adulthood? What are the predictors of early glycaemic control?PopulationExposureOutcomeChildhood or paediatric onset diabetes or juvenile diabetes diagnosis or newly diagnosed children or young persons or young people or children or young or adolescent or teen or youth or adult T1D patient or type 1 diabetes or T1D or type 1 diabetes mellitus or T1DM or DM1 or type 1 or IDDM or insulin dependent or non-insulin dependent or childhood onset diabetes or childhood onset T1D or auto-immune or autoimmune or sudden onset or uncontrolled or labile or brittleEarly diabetes control or HbA1c trajectories or HbA1c trends or glycaemic trajectories or glycosylated or HbA1c or A1c or Hemoglobin A or HbA(1c) level or glycaemic control or glucose control or diabetes control or early intensive intervention or intensive or conventional or standard or regular or optimised or tight control or strict control or usual or routine or therapy or treatment or intervention or management or insulin use or injection or dose insulin injections or intensive therapy or insulin pumpDiabetic or diabetes complications or complications or side effects or adverse events or acute complications or chronic complications or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine albumin excretion or microalbuminuria or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retinopathy or blindness or vascular disease or vascular complications or microvascular disease or microvascular complications or macrovascular disease or macrovascular complications or cardiovascular disease or MI or myocardial infarction or stroke or coronary artery disease or cerebrovascular disease or peripheral vascular disease or blood pressure or BP or statin or death or mortality or Pathology or metabolism or metabolic memory

Six electronic databases (Medline and Embase (via OVID), Web of Science (via Thomson Reuters), Cinhal (via EBSCO), Scopus (via Elsevier) and Cochrane Library) were double-searched in parallel (by VMP and HC to minimise study selection bias) in December 2014, without time period or language restrictions, by using a combination of free text and Thesaurus or Mesh terms (see Additional file [1](#MOESM1){ref-type="media"}: Electronic database search strategy.pdf). All identified articles from individual databases (Medline, *n* = 13,039; Embase, *n* = 645; Web of Science, *n* = 2323; Cinahl, *n* = 984; Scopus, *n* = 1540 and Cochrane, *n* = 3242) were imported into an endnote file and de-duplicated, which resulted in 17,915 articles for further review. This will be supplemented by hand-searching reference lists and contacting authors of included studies and relevant reviews (see Fig. [1](#Fig1){ref-type="fig"} for a flow diagram of the study selection process).Fig. 1Flowchart presenting an overview of the search results

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Interventional studies, i.e. randomised control trials (RCTs) and non-RCTs, targeting glycaemic control (within 2 years of diagnosis of T1D in children and young people) and describing an association with health outcomes will be included. Observational, i.e. cohort and cross-sectional studies that quantified the association between early glycaemic control (within 2 years of diagnosis of T1D) AND risk of future complications in children and young people aged 0 to 25 years at baseline, will be included. Qualitative studies that give a deeper background understanding on the predictors of early HbA1~c~ in this age group will also be included.

Our exclusion criteria are as follows: non-human or animal studies, studies with population selected for other diseases/co-morbidities or clinical conditions, studies in adults aged more than 25 years at baseline, studies in other types of diabetes such as type 2 diabetes (T2D) or gestational diabetes. Quantitative studies not reporting clinical outcomes or quantitative studies that measured glycaemic control but did not describe an association with outcome variables will also be excluded. The overlapping eligibility criteria for the reviews are presented as inclusion/exclusion criteria in Table [2](#Tab2){ref-type="table"}.Table 2Inclusion and exclusion criteria for review of evidence on the following: 1. Does early HbA1c predict later complications? 2. What factors predict early HbA1c?Inclusion criteriaExclusion criteriaFor reviews 1 and 2 Interventional studies (RCT's and non-RCT's) targeting glycaemic control (within 2 years of diagnosis of T1D) and described an association with health outcomesNon-human studiesSelection of population based on other diseases/co-morbiditiesAdults aged more than 25 years at baselineStudies on T2DQuantitative studies not reporting clinical outcomesQuantitative studies that measured glycaemic control but did not describe an association with outcome variables Non-intervention/observational, i.e. cohort and cross-sectional (XS) studies that quantified the association between early glycaemic control (within 2 years of diagnosis of T1D) AND risk of future complications in children and young people aged 0 to 25 years at baselineFor review 1: longitudinal studies with a follow-up of ≥5 years from diagnosisFor review 2: qualitative studies that give a deeper background understanding on the topic

Study selection procedure {#Sec5}
-------------------------

A 10 % proportion (1792) of the total abstracts and titles will be randomly selected and double screened (DC and VMP), based on a piloted screening protocol. Results will be compared to ensure less than 5 % discrepancy between reviewers. Any disagreements will be resolved through discussion and re-examining of abstract. Following which, all 17,915 abstracts and titles will be screened independently (VMP). Full texts of abstracts appearing to meet the inclusion criteria will be ordered for further review and data extraction. Descriptive mapping of existing evidence will be undertaken to establish gaps in evidence-base and to ascertain that there is sufficient data meriting review.

Data extraction and quality assessment {#Sec6}
--------------------------------------

A data extraction Excel spread sheet will be piloted to ensure consistency of data extraction between reviewers. One of the reviewers (VMP) will then systematically review and extract detailed data of all studies meeting the inclusion criteria. A proportion of the studies will be double-reviewed by a second reviewer, and any differences will be discussed and resolved. Details of data will be extracted according to study designs, i.e. interventional, observational and qualitative (see Table [3](#Tab3){ref-type="table"}).Table 3Details of data extracted for different study designsIntervention studiesObservational/non-intervention studies (cross-sectional and prospective)Qualitative studiesStudy idStudy idStudy idAuthorAuthorAuthorYearYearYearCountryCountryCountryAge rangeAge rangeAgeAverage ageAverage ageDesignSex (male to female ratio)Sex (male to female ratio)Number of participantsDesign: cRCT, RCT, quasiRCT, before-after, etc.EthnicitySample/recruitmentNumber of participantsSocioeconomic statusFindings/direct quotesSample/recruitment, e.g. general population representative sample or specialist groups (deprivation, ethnicity, geography, etc.)Design (cross-sectional/prospective)Author conclusionsIntervention details (pump/injection, duration, dosage)Number of participantsCommentsControlSample/recruitment, e.g. general population representative sample or specialist groupsAuthor emailSetting (home, primary care, secondary care)Exposure examinedIntervention providerMeasurement of exposureNumber of sitesMeasurement conducted by Level of glycemic controlOutcome (complications, metabolic memory---separate row for each outcome investigated)Setting (home, primary care, secondary care)Measurement of outcome (objective)Outcome (complications, metabolic memory---separate row for each outcome investigated)AnalysisMeasurement of outcome (objective)Effect---point estimateAnalysis Effect---upper confidence interval Effect---lower confidence intervalFollow-up durationEffectCommentsAuthor emailAuthor emailComments

Included studies will be systematically quality-assessed against pre-set quality criteria by using standard quality assessment checklists designed by the EPPI centre for specific (intervention, observational and qualitative) study designs (see Table [4](#Tab4){ref-type="table"}).Table 4Quality assessment criteria by study designFor intervention studiesFor observational (prospective cohort and cross-sectional) studiesFor qualitative studiesTotal quality assessment score (maximum of 8) was derived for the fulfilment of following criteria:Total quality assessment score (maximum of 6) was derived for the fulfilment of following criteria:Total quality assessment score (maximum of 12) was derived for the fulfilment of following criteria:1) Randomisation1) More than 50 participants analysed1) Research questions clearly stated2) Effect of intervention reported for all outcomes2) Studies representing general population2) Approach appropriate for the research question3) Pre-intervention data on all outcomes3) Prospective study design3) Qualitative approach clearly justified4) Post-intervention data on all outcomes4) Adjusted/multivariate analysis4) Study context clearly described5) Allocation concealment5) Objective measure of outcome5) Role of the researcher clearly described6) Blinding6) Objective measure of exposure6) Sampling method clearly described7) Objective measurement of outcome7) Sampling strategy appropriate for the research question8) Retention \>70 %8) Method of data collection clearly describedStudies with small sample size (*n* \< 50) and no control group were considered to provide lower quality evidence and not scored9) Data collection method appropriate10) Method of analysis clearly described11) Analysis appropriate for the research question12) Conclusions supported by sufficient evidence

Data syntheses {#Sec7}
--------------

Extracted data will be analysed and synthesised using a narrative and either forest plots or harvest plots (for quantitative evidence) and thematic analyses (for qualitative studies). To get a deeper understanding of the predictors of early glycaemic control in reducing complications in childhood and adult life, we will integrate qualitative and quantitative evidence using mixed methods or parallel synthesis approach.

### Intervention studies {#Sec8}

Meta analyses will be attempted to synthesise data from RCTs and Non-RCTs, assessed with low risk of bias and the results presented as forest plots \[[@CR50]\]. Subgroup analyses by intervention type will be undertaken, subject to data type and quality.

### Observational studies {#Sec9}

Harvest plots \[[@CR51]\] will be used to summarise data if meta-analysis/meta-regression is not possible. The evidence will be presented as bar charts and symbols. Colour (black, dark grey and light grey) of bar will represent quality of study, with lighter bars representing studies of low quality. Height of bar will indicate the study size, and position of the bar will summarise the direction and strength of the association (++, +, 0, −, −−). Categorical and continuous outcome variable results will be consistently recoded, such that a single or double + symbolises higher risk for complications, and a single or double − symbolises a lower risk for complications \[[@CR52], [@CR53]\].

### Qualitative studies {#Sec10}

Evidence from qualitative studies will be synthesised thematically, and the results will be integrated with the quantitative evidence using the parallel synthesis or mixed methods approach \[[@CR54], [@CR55]\]. Recommendations for future interventions and policy decisions will be drawn by interpreting quantitative findings, using the themes identified from qualitative studies.

Discussion {#Sec11}
==========

The importance of diabetes-related complications may be underestimated. Data from the 2010--2011 National Paediatric Diabetes Audit (NPDA) showed that only 5.8 % of all children and young persons with diabetes are recorded as having received all the National Institute for Health and Care Excellence (NICE) recommended care processes aimed at reducing risk of chronic complications \[[@CR56]\]. This percentage increased to 16.1 % in the 2013--2014 NPDA, which may reflect the incentivising effect of the recent introduction of the best practice tariff for paediatric diabetes care in the UK \[[@CR57]\]. However, this percentage of optimum service delivery still compares unfavourably to adults with diabetes (\>60 % received all recommended care processes during the 2011--2012 and 2012--2013 National Diabetes Audits (NDA)) and is very low when compared internationally \[[@CR16], [@CR58]\].

In a clinic setting, aiming for tight glycaemic targets remains difficult to achieve, outside of a clinical trial. The mean HbA1~c~ level in the intensively treated group participating for more than 20 years ago in the DCCT was lower than the HbA1~c~ levels in most patients today \[[@CR59], [@CR60]\]. The intensive group achieved HbA1~c~ levels of 7 % on an average compared with 8.3 % among more than 25,000 patients from 67 US centres in the T1D exchange \[[@CR59]\], and this was achieved without modern advances in therapy, such as insulin analogues and continuous glucose monitors. Therefore, we need to understand the effect, predictors and trends of early glycaemic control on complications risk in childhood and adults.

Our second aim is to look at which factors predict early HbA1~c~. These could be factors across the whole biopsychosocial model. For example, there may be social factors (deprivation, ethnic), psychological factors (teenage behaviour, fear of hypoglycaemia), physiological factors (glycation index) as well as wider cultural factors (the family, school, clinic setting, etc.).

By systematically reviewing evidence on effect of glycaemic control within first 2 years of T1D diagnosis and tracking with increasing diabetes duration, this will help identify predictors of early glycaemic control and understand future risk for complications in the paediatric population.

How this review compares with previous reviews in children and young adults {#Sec12}
---------------------------------------------------------------------------

To our knowledge, this is the first review to robustly investigate evidence on the association of early glycaemic control in childhood-onset T1D with future complications risk. Furthermore, this is the first review to rigorously and systematically integrate quantitative (both intervention and observational) and qualitative evidence on this topic \[[@CR55]\]. Evidence synthesised this way is holistic and more reliable than syntheses of any one type of research in isolation.

Dissemination and updating plans {#Sec13}
--------------------------------

Results of the review will be disseminated through peer-reviewed publications, conference presentations and at meetings. The review will be updated if significant new evidence becomes available.

Additional file {#Sec14}
===============

Additional file 1:**Electronic database search strategy.**

DCCT

:   Diabetes Control and Complications Trial

EPPI

:   Evidence for Policy and Practice Information

HbA1~c~

:   glycated haemoglobin A1~c~

NDA

:   National Diabetes Audit

NICE

:   National Institute for Health and Care Excellence

NPDA

:   National Paediatric Diabetes Audit

PROSPERO

:   International Prospective Register for systematic Reviews

RCT

:   randomised control trial

T1D

:   type 1 diabetes

**Competing interests**

No potential conflict of interest was reported by the authors.

**Authors' contributions**

VMP was the lead reviewer, created the study design and search strategy, searched electronic databases for literature and wrote the first draft of the protocol. RA conceptualised the project, was project lead, advised on the trajectories of the project, participated in the study design and helped revise the manuscript. DC double screened a proportion of titles/abstracts, participated in the study design and helped revise the manuscript. ARK participated in the design of the study and helped revise the manuscript. DTR participated in the design of the study and helped revise the manuscript. TS was overall project lead, advised on the trajectories of the project, participated in the study design and helped revise the manuscript. RV advised on the trajectories of the project, participated in the study design and helped revise the manuscript. JE advised on the trajectories of the project, participated in the study design and helped revise the manuscript. All authors contributed to the study design, critical revision of the manuscript and approved the final version.

Our sincere thanks to the funders and the following from the University College London: Miss Heather Chester (HC) for her help with the literature search strategy and Mrs Linda Haines for her help and support throughout. The authors also thank the following collaborators for their comments and guidance on the project: Prof. David Dunger, Department of Paediatrics, University of Cambridge; Dr. Bob Young, consultant diabetologist and CMIO, Diabetes and Endocrinology, Salford Royal Foundation NHS Trust; clinical lead, National Diabetes Audit (NDA) and National Cardiovascular Intelligence Network (NCVIN), Dr. Alison Elderfield and project manager, National Paediatric Diabetes Audit Research and Policy Division; Royal College of Paediatrics and Child Health, Dr Justin Warner, consultant in Paediatric Endocrinology and Diabetes, honorary Senior Lecturer Cardiff University, and clinical lead for the National Paediatric Diabetes Audit; and Dr. Fiona Campbell, national clinical lead for the Children and Young People's Diabetes Network and Peer Review Quality Assurance Programme, NHS England.

Funding {#FPar1}
=======

This project is funded by UCL IMPACT/Department of Health PhD Studentship 2014/15. This is an independent report commissioned and funded by the Policy Research Programme in the Department of Health. The views expressed are not necessarily those of the department.
